{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-012303","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.460604+00:00","generated_at":"2026-05-23T11:59:01.384415+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals boosts ATM offering capacity to $20M; previously sold $1.8M","bullets":["Maximum aggregate offering price increased to $20,000,000 under ATM agreement with H.C. Wainwright & Co.","Approximately $1.8 million in common stock sold prior to the increase.","Prospectus supplement filed on April 17, 2025 to register the additional shares.","Legal opinion on share validity filed as Exhibit 5.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-012303","json":"https://secwatch.observer/filing/0001437749-25-012303.json","markdown":"https://secwatch.observer/filing/0001437749-25-012303.md","text":"https://secwatch.observer/filing/0001437749-25-012303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925012303/0001437749-25-012303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925012303/nrxp20250417_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T11:59:01.384415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}